Aims: We studied clinical factors in association with the glucagon stimulation test and daily and day-to-day glucose variability as determined by continuous glucose monitoring (CGM).

Methods: We performed a cross-sectional analysis of type 2 diabetes (T2DM; insulin-treated, n=83; not insulin-treated, n=126) patients who underwent the glucagon stimulation test and over 72 h of continuous glucose monitoring. Correlations of clinical factors with the mean amplitude of glycemic excursions (MAGE), percentage coefficient of variation for glucose (%CV), and mean of daily differences (MODD) in CGM were analyzed.

Results: In T2DM with insulin therapy, age and HbA1c were correlated with MAGE and %CV; FPG was correlated with MAGE and MODD; and the increment of CPR (ΔCPR) was inversely correlated with MAGE, %CV, and MODD. In T2DM without insulin therapy, age, diastolic blood pressure, and triglycerides were correlated with MODD; ΔCPR was inversely correlated with %CV; HbA1c was correlated with MAGE and MODD; the use of α-glucosidase inhibitors was inversely correlated with %CV; and the use of sulfonylurea (SU) was correlated with MAGE and %CV.

Conclusions: Insulin secretion is related to glucose variability in insulin-treated T2DM. Poor glycemic control greatly contributes to glucose variability in T2DM. SU administration increases the daily glucose variability in T2DM without insulin therapy.


M. Ohara: None. H. Nagaike: None. S. Goto: Research Support; Spouse/Partner; DENKA SEIKEN CO., LTD. H. Kushima: None. M. Hiromura: None. T. Yamamoto: None. Y. Mori: None. T. Fukui: None. T. Hirano: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at